Drug Trial Radar · NCT07598318
Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations
Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
164
Planned (sponsor's estimate)
Start
May 20, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Sir Run Run Shaw HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study tests whether adding becotatug vedotin (EGFR-ADC) to standard chemotherapy plus immunotherapy improves outcomes compared to chemotherapy plus immunotherapy alone as first-line treatment for patients with advanced or metastatic biliary tract cancer whose tumors carry EGFR mutations. Participants will be randomly assigned to receive either the experimental combination (becotatug vedotin + pucotenlimab + gemcitabine + cisplatin) or the control combination (pucotenlimab + gemcitabine + cisplatin). The main goal is to see if the experimental group has a higher objective response rate (tumor shrinkage rate). This is a randomized, controlled, open-label, multicenter study led by Sir Run Run Shaw Hospital, Zhejiang University, with Dr. Chen Mingyu as the principal investigator.
Conditions
- Cholangiocarcinoma
Interventions
Becotatug VedotinDrug
Becotatug Vedotin:2mg/kg,IV,Q3W,D1
PucotenlimabDrug
Pucotenlimab:200mg,IV,Q3W,D1
GemcitabineDrug
Gemcitabine:1000mg/m²,IV,D1、D8,Q3W. Each course lasts for 8 weeks. The maximum treatment duration is 8 courses.
CisplatinDrug
Cisplatin:25mg/m²,IV,D1、D8,Q3W. Each course lasts for 8 weeks. The maximum treatment duration is 8 courses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: After two treatment cycles(each cycle is 28 days)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.